We are living through a scientific renaissance – fueled by advancements in biology and technology. The years ahead will have a dramatic impact on human health.
At Pfizer, we are in the midst of an 18-month period during which we expect to launch 19 new medicines and vaccines across a range of therapeutic areas. This is unprecedented in our company history and, if successful, will deliver a wave of potential new innovations for patients across multiple therapeutic areas.
The past years have shown what is possible when we aim higher than we imagined possible. We learned how to work at light speed and have applied learnings from our work on the Covid-19 vaccine and antiviral to other R&D programs. We continue to make strides to further improve our industry-leading success rates and cycle times.
Pfizer is working to change the lives of patients around the world through our R&D efforts, our commitment to provide our portfolio of medicines and vaccines to lower income countries at a not-for-profit price, our creative yet disciplined approach to business development and more.
No other sector has done more good for the world than the life sciences sector, and I am extremely proud to have spent my entire career at one of the sector’s leading companies. Our innovations have helped save, extend, and improve lives for decades, and we are focused on delivering even more breakthroughs so we can reach even more patients in the future.
